| Home | Log In | Register | Our Services | My Account | Contact | Help |
- 26 Sep 2012 20:57

- 07 Nov 2014 12:46
- 142 of 183
- 07 Nov 2014 13:07
- 143 of 183
- 07 Nov 2014 13:23
- 144 of 183
- 07 Nov 2014 13:59
- 145 of 183
- 07 Nov 2014 14:42
- 146 of 183
- 20 Nov 2014 13:27
- 147 of 183
- 27 Nov 2014 08:17
- 148 of 183
- 19 Dec 2014 15:53
- 149 of 183
- 02 Jan 2015 16:08
- 150 of 183
- 14 Jan 2015 15:45
- 151 of 183
- 14 Jan 2015 17:49
- 152 of 183
- 15 Jan 2015 09:43
- 153 of 183
- 05 Feb 2015 19:39
- 154 of 183
- 05 Mar 2015 18:28
- 155 of 183
- 12 Mar 2015 16:49
- 156 of 183
- 17 Mar 2015 10:03
- 157 of 183
- 22 Mar 2015 20:03
- 158 of 183
- 22 Mar 2015 22:34
- 159 of 183
- 02 Apr 2015 16:38
- 161 of 183
Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsWednesday 29th April 2015
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • John Cronin, Executive Chairman - Cyan Technology (CYAN) • Crispin Simon, CEO - REX Bionics (RXB) • Jog Dhody, CFO - Regenersis (RGS) • Dr. Satu Vainikka, CEO - Valirx (VAL) | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
Cyan is an integrated system design company headquartered in Cambridge, with customers, staff and partners across many of the world’s largest emerging markets. It provides a communication platform that enables the measurement and control of energy consumption for smart metering and lighting. Cyan is focussed on emerging markets, where it’s low cost, low power solution provides significant customer benefits. It delivers integrated solutions to utilities, municipalities and local authorities, with customer wins to date in India, Brazil and China |
Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets. |
Rex Bionics Plc (The Rex Bionics Group) is the global technology leader in robotic walking devices (REX). Uniquely, REX® provides independent mobility to wheelchair users and other mobility impaired persons using advanced robotic technology, custom-designed electromechanical actuators, precision engineering, and specialised networking systems. Today there are two primary REX devices available; an adjustable REX Rehab for use in rehabilitation centres, and a streamlined, fit-for-purpose REX Personal made for each individual’s specific medical and physical requirements enabling the user to perform tasks and functions previously unavailable. Rex Bionics is a rapidly growing, exciting, innovative organisation which is proud to provide advanced robotics technology to people everywhere. |
Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |